85446-05-5Relevant academic research and scientific papers
Carbazole compound and application thereof in preparation of medicines for treating fatty liver and 2 type diabetes and other metabolic related diseases
-
Paragraph 0072-0075, (2021/09/21)
The invention relates to a carbazole compound and application thereof in preparation of drugs for treating metabolic related diseases such as fatty liver and 2 type diabetes, wherein the structural general formula of the carbazole compound is as shown in
Design, synthesis and biological activity evaluation of novel carbazole-benzylpiperidine hybrids as potential anti Alzheimer agents
Edraki, Najmeh,Faghih, Zeinab,Iraji, Aida,Nadri, Hamid,Rezaei, Zahra,Sadeghian, Batool,Sadeghian, Issa,Sakhteman, Amirhossein
, (2020/07/21)
Alzheimer's disease (AD) as the most common form of dementia in aged people, is an intricate neurodegenerative disease. Therefore, a novel strategy so-called multi-target-directed ligand has received much attention for the effective treatment of AD. In this study a series of novel carbazole-benzylpiperidine hybrids 9a-m was designed, synthesized and evaluated as acetylcholinesterase and butyrylcholinesterase inhibitors. Moreover, some of these compounds were evaluated for anti β-secretase (BACE1) activity and metal chelation properties. Among the synthesized compounds, compounds 9b (IC50 = 16.5 μM for AChE and IC50 = 0.59 μM for BuChE) and 9c (IC50 = 26.5 μM for AChE and IC50 = 0.18 μM for BuChE) showed the highest inhibitory activity against acetylcholinesterase and butyrylcholinesterase. Furthermore, these compounds (9b and 9c) displayed interaction with Zn2+ ion and compound 9c showed moderate inhibitory activity against BACE1 (24.5% at 50 μM). Kinetic and docking studies exhibited that these compounds likely act as a non-competitive inhibitor able to interact with the catalytic active site (CAS) and peripheral anionic site (PAS) of acetylcholinesterase simultaneously.
With chiral center carbazolyl isopropanolamine derivatives of the preparation method and application of (by machine translation)
-
Paragraph 0056; 0057; 0062; 0067, (2019/05/04)
The invention relates to a with chiral center carbazolyl isopropanolamine derivatives of the preparation method and application. This compound has the general formula (I) indicated by the structure: The compound such as [...] Phaeosphaeria, tobacco wilt b
Identification of racemic and chiral carbazole derivatives containing an isopropanolamine linker as prospective surrogates against plant pathogenic bacteria: In vitro and in vivo assays and quantitative proteomics
Zhao, Yong-Liang,Huang, Xing,Liu, Li-Wei,Wang, Pei-Yi,Long, Qing-Su,Tao, Qing-Qing,Li, Zhong,Yang, Song
, p. 7512 - 7525 (2019/08/21)
Recent observations on the emergence of drug-resistant plant pathogenic bacteria have highlighted and elicited an acute campaign to develop novel, highly efficient antibiotic surrogates for managing bacterial diseases in agriculture. Thus, a type of racemic and chiral carbazole derivative containing an isopropanolamine pattern was systematically synthesized to discover low-cost and efficient antibacterial candidates. Screening results showed that compounds 2f, 6c, and 2j could significantly suppress the growth of tested plant pathogens, namely Xanthomonas oryzae pv oryzae, X. axonopodis pv citri, and Pseudomonas syringae pv actinidiae, and provided the corresponding EC50 values of 1.27, 0.993, and 0.603 μg/mL, which were significantly better than those of existing commercial drugs. In vivo studies confirmed their prospective applications for controlling plant bacterial diseases. Label-free quantitative proteomics analysis indicated that compound 2f could dramatically induce the up- and down-regulation of a total of 247 differentially expressed proteins, which was further validated by the parallel reaction monitoring technique. Moreover, fluorescence spectra and SEM images were obtained to further explore the antibacterial mechanism.
Potential Antimicrobial Isopropanol-Conjugated Carbazole Azoles as Dual Targeting Inhibitors of Enterococcus faecalis
Zhang, Yuan,Tangadanchu, Vijai Kumar Reddy,Cheng, Yu,Yang, Ren-Guo,Lin, Jian-Mei,Zhou, Cheng-He
supporting information, p. 244 - 249 (2018/03/21)
A series of isopropanol-bridged carbazole azoles as potential antimicrobial agents were designed and synthesized from commercial carbazoles. Bioassay revealed that 3,6-dichlorocarbazolyl triazole 3f could effectively inhibit the growth of E. faecalis with minimal inhibitory concentration of 2 μg/mL. The active molecule 3f showed lower propensity to trigger the development of resistance in bacteria than norfloxacin and exerted rapidly bactericidal ability. Compound 3f also exhibited low cytotoxicity to normal mammalian RAW264.7 cells. Further mechanism exploration indicated that conjugate 3f was membrane active against E. faecalis and could form 3f-DNA complex by intercalating into DNA of resistant E. faecalis, which might be responsible for its antimicrobial action. Molecular docking showed an efficient binding of triazole derivative 3f with DNA gyrase enzyme through noncovalent interactions.
Carbazole alkamine compound and preparation method thereof and application for parasitic disease resistance
-
Paragraph 0182; 0183; 0184; 0187; 0188, (2017/05/10)
The invention provides a carbazole alkamine compound and a preparation method thereof and application for a parasitic disease resistance aspect. Specifically, the invention provides a racemic modification of the compound shown as type (A) and an enantiomer or salt capable of being accepted by pharmacy of the enantiomer. The compound has excellent anti-schistosoma and anti-hydatid cyst activity. According to the carbazole alkamine compound and the preparation method thereof and the application for the parasitic disease resistance aspect, the design is reasonable, the source of used raw materials is wide, the preparation method is easy and convenient and suitable for utility and can be applied to parasitic disease resistance drug preparation. Type A (please see the specifications for the chemical structural formula)
Novel carbazole aminoalcohols as inhibitors of β-hematin formation: Antiplasmodial and antischistosomal activities
Wang, Weisi,Li, Qiang,Wei, Yufen,Xue, Jian,Sun, Xiao,Yu, Yang,Chen, Zhuo,Li, Shizhu,Duan, Liping
, p. 191 - 199 (2017/04/13)
Malaria and schistosomiasis are two of the most socioeconomically devastating parasitic diseases in tropical and subtropical countries. Since current chemotherapeutic options are limited and defective, there is an urgent need to develop novel antiplasmodials and antischistosomals. Hemozoin is a disposal product formed from the hemoglobin digestion by some blood-feeding parasites. Hemozoin formation is an essential process for the parasites to detoxify free heme, which is a reliable therapeutic target for identifying novel antiparasitic agents. A series of novel carbazole aminoalcohols were designed and synthesized as potential antiplasmodial and antischistosomal agents, and several compounds showed potent in?vitro activities against Plasmodium falciparum 3D7 and Dd2 strains and adult and juvenile Schistosoma japonicum. Investigations on the dual antiparasitic mechanisms showed the correlation between inhibitory activity of β-hematin formation and antiparasitic activity. Inhibiting hemozoin formation was identified as one of the mechanisms of action of carbazole aminoalcohols. Compound 7 displayed potent antiplasmodial (Pf3D7 IC50?=?0.248?μM, PfDd2 IC50?=?0.091?μM) and antischistosomal activities (100% mortality of adult and juvenile schistosomes at 5 and 10?μg/mL, respectively) and exhibited low cytotoxicity (CC50?=?7.931?μM), which could be considered as a promising lead for further investigation. Stoichiometry determination and molecular docking studies were also performed to explain the mode of action of compound 7.
Bromomethylthioindole Inspired Carbazole Hybrids as Promising Class of Anti-MRSA Agents
Cheng, Chia-Yi,Chang, Chun-Ping,Lauderdale, Tsai-Ling Yang,Yu, Guann-Yi,Lee, Jinq-Chyi,Jhang, Yi-Wun,Wu, Chien-Huang,Ke, Yi-Yu,Sadani, Amit A.,Yeh, Ching-Fang,Huang, I-Wen,Kuo, Yi-Ping,Tsai, De-Jiun,Yeh, Teng-Kuang,Tseng, Chen-Tso,Song, Jen-Shin,Liu, Yu-Wei,Tsou, Lun K.,Shia, Kak-Shan
supporting information, p. 1191 - 1196 (2016/12/18)
Series of N-substituted carbazole analogues bearing an indole ring were synthesized as anti-methicillin-resistant Staphylococcus aureus (MRSA) agents from a molecular hybridization approach. The representative compound 19 showed an MIC = 1 μg/mL against a panel of MRSA clinical isolates as it possessed comparable in vitro activities to that of vancomycin. Moreover, compound 19 also exhibited MIC = 1 μg/mL activities against a recent identified Z172 MRSA strain (vancomycin-intermediate and daptomycin-nonsusceptible phenotype) and the vancomycin-resistant Enterococcus faecalis (VRE) strain. In a mouse model with lethal infection of MRSA (4N216), a 75% survival rate was observed after a single dose of compound 19 was intravenously administered at 20 mg/kg. In light of their equipotent activities against different MRSA isolates and VRE strain, the data underscore the importance of designed hybrid series for the development of new N-substituted carbazoles as potential anti-MRSA agents.
Carbazole-rivastigmine diad and pharmaceutical composition and application thereof
-
Paragraph 0024, (2016/12/26)
The invention provides compounds of the structure as shown in the description or pharmaceutical salt, a pharmaceutical composition and application of the compounds. The compounds relate to a series of carbazole and rivastigmine diads. The carbazole and ri
Synthesis and biological evaluation of novel 1,2,4-triazine derivatives bearing carbazole moiety as potent α-glucosidase inhibitors
Wang, Guangcheng,Wang, Jing,He, Dianxiong,Li, Xin,Li, Juan,Peng, Zhiyun
, p. 2806 - 2809 (2016/06/09)
A new series of 1,2,4-triazine derivatives bearing carbazole moiety 7a-7p were designed, synthesized, and evaluated for their α-glucosidase inhibitory activity. The majority of the screened compounds displayed potent α-glucosidase inhibitory activity, with IC50 values in the range of 4.27 ± 0.07-47.75 ± 0.25 μM as compared to the standard drug acarbose. Among the series, compound 7k represented the most potent α-glucosidase inhibitory activity with IC50 values of 4.27 ± 0.07 μM. Kinetic analysis revealed that compound 7k is a non-competitive inhibitor with a Ki of 4.43 μM. Furthermore, the binding interactions of compound 7k with α-glucosidase was confirmed through molecular docking. This study showed these 1,2,4-triazine derivatives bearing carbazole moiety as a new class of α-glucosidase inhibitors.
